Cardiac arrhythmias are currently among the most likely causes of sudden death. Conducting research on the pharmaceutical market of drugs used for the pharmacotherapeutic correction of arrhythmias allows us to assess not only their clinical efficacy and safety, but also economic, regulatory, and innovation aspects that affect the availability and quality of therapy.

The aim of this work is to research the market of antiarrhythmic drugs (AADs), aimed at improving pharmaceutical developments and meeting patient needs in the context of global epidemiological and economic challenges.

Materials and methods. To analyze the assortment structure of AADs, information from the State Register of Medicinal Products of Ukraine, the National List of Essential Medicines; open statistical resources of the Ministry of Health of Ukraine; tabletki.ua and online data of pharmacy chains, instructions for medical use of drugs was used.

Results. The AADs market in Ukraine has a sufficient range for the treatment of arrhythmias of various origins, which is confirmed by the presence of 63 drugs under 14 international non-proprietary names. The largest market share is occupied by selective beta-adrenergic blockers and class III drugs, which indicates their high clinical demand. However, in terms of dosage forms, the market includes only oral (76.2 %) and injectables. The vast majority of antiarrhythmic drugs on the domestic market are monocomponent drugs, which allows doctors to flexibly select individual treatment regimens for patients.

Conclusions. To ensure better access to pharmacotherapy for cardiac arrhythmias, it is necessary to expand the range, especially in groups with fewer drugs, and to stimulate the development of new, more effective agents, considering clinical needs and current international guidelines. A significant proportion of AADs is included in the State Formulary and the National List of Essential Medicines, which increases their availability to the population. However, to further increase accessibility, the list of drugs included in the “Affordable Medicines” program should be expanded, as well as reimbursement mechanisms for innovative and expensive antiarrhythmic drugs should be introduced. The development of new innovative application dosage forms, for example with amiodarone, could improve bioavailability, patient compliance, and safety of therapy, contributing to better heart rhythm control without significant risk of complications, as noted in current clinical guidelines.